Modified Hemagglutination Tests for COVID-19 Serology in Resource-Poor Settings: Ready for Prime-Time?

Focosi, Daniele; Franchini, Massimo; Maggi, Fabrizio

doi:10.3390/vaccines10030406

Cited by 2 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, such a blanket approach would result in infection-naive individuals initially receiving one vaccination only, which provides suboptimal protection 8 . To reduce this risk, where previous infection is expected to be high, another option would be to stratify individual vaccination based on an affordable and rapid lateral flow immunoassay (LFIA) for antibody detection, and information on previous PCR positivity 27 – 31 . An extensive comparison of different fingerprick-based LFIA antibody tests reported high specificity (98.8–99.8%) 32 , meaning that there would be few false positives in a high prevalence setting.…”

Section: Resultsmentioning

confidence: 99%

SARS-CoV-2 antibody trajectories after a single COVID-19 vaccination with and without prior infection

et al. 2022

View full text Add to dashboard Cite

Given high SARS-CoV-2 incidence, coupled with slow and inequitable vaccine roll-out in many settings, there is a need for evidence to underpin optimum vaccine deployment, aiming to maximise global population immunity. We evaluate whether a single vaccination in individuals who have already been infected with SARS-CoV-2 generates similar initial and subsequent antibody responses to two vaccinations in those without prior infection. We compared anti-spike IgG antibody responses after a single vaccination with ChAdOx1, BNT162b2, or mRNA-1273 SARS-CoV-2 vaccines in the COVID-19 Infection Survey in the UK general population. In 100,849 adults median (50 (IQR: 37–63) years) receiving at least one vaccination, 13,404 (13.3%) had serological/PCR evidence of prior infection. Prior infection significantly boosted antibody responses, producing higher peak levels and/or longer half-lives after one dose of all three vaccines than those without prior infection receiving one or two vaccinations. In those with prior infection, the median time above the positivity threshold was >1 year after the first vaccination. Single-dose vaccination targeted to those previously infected may provide at least as good protection to two-dose vaccination among those without previous infection.

show abstract

Section: Resultsmentioning

confidence: 99%

SARS-CoV-2 antibody trajectories after a single COVID-19 vaccination with and without prior infection

et al. 2022

View full text Add to dashboard Cite

show abstract

“…For the same reasons, hemagglutination tests (HAT) could be easily adjusted to face the issue of VOC [ 31 ]. However, HATs are not certified for diagnostics, even if they are considered helpful tools in low-resource settings [ 32 , 33 ].…”

Section: Discussionmentioning

confidence: 99%

Correlation between In Vitro Neutralization Assay and Serological Tests for Protective Antibodies Detection

Bonifacio

Laterza

Vinella

et al. 2022

IJMS

View full text Add to dashboard Cite

Serological assays are useful in investigating the development of humoral immunity against SARS-CoV-2 in the context of epidemiological studies focusing on the spread of protective immunity. The plaque reduction neutralization test (PRNT) is the gold standard method to assess the titer of protective antibodies in serum samples. However, to provide a result, the PRNT requires several days, skilled operators, and biosafety level 3 laboratories. Therefore, alternative methods are being assessed to establish a relationship between their outcomes and PRNT results. In this work, four different immunoassays (Roche Elecsys® Anti SARS-CoV-2 S, Snibe MAGLUMI® SARS-CoV-2 S-RBD IgG, Snibe MAGLUMI® 2019-nCoV IgG, and EUROIMMUN® SARS-CoV-2 NeutraLISA assays, respectively) have been performed on individuals healed after SARS-CoV-2 infection. The correlation between each assay and the reference method has been explored through linear regression modeling, as well as through the calculation of Pearson’s and Spearman’s coefficients. Furthermore, the ability of serological tests to discriminate samples with high titers of neutralizing antibodies (>160) has been assessed by ROC curve analyses, Cohen’s Kappa coefficient, and positive predictive agreement. The EUROIMMUN® NeutraLISA assay displayed the best correlation with PRNT results (Pearson and Spearman coefficients equal to 0.660 and 0.784, respectively), as well as the ROC curve with the highest accuracy, sensitivity, and specificity (0.857, 0.889, and 0.829, respectively).

show abstract

Modified Hemagglutination Tests for COVID-19 Serology in Resource-Poor Settings: Ready for Prime-Time?

Cited by 2 publications

References 30 publications

SARS-CoV-2 antibody trajectories after a single COVID-19 vaccination with and without prior infection

SARS-CoV-2 antibody trajectories after a single COVID-19 vaccination with and without prior infection

Correlation between In Vitro Neutralization Assay and Serological Tests for Protective Antibodies Detection

Contact Info

Product

Resources

About